Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc.

Key Points

• Assetmark Inc. trimmed its stake in Gilead by 7.3% to 144,683 shares (about $17.76M), and company insiders have sold a total of 299,280 shares worth $42.92M in the past 90 days — including CEO Daniel Patrick O'day and Johanna Mercier, with some trades executed under Rule 10b5‑1 plans.
• Gilead beat recent quarterly EPS estimates and set FY 2026 guidance of $8.45–$8.85 EPS, raised its quarterly dividend to $0.82 (2.4% yield), and benefits from mostly constructive analyst coverage (24 Buys vs. 4 Holds) with an average target of $156.77.

Assetmark Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 144,683 shares of the biopharmaceutical company's stock after selling 11,435 shares during the period. Assetmark Inc.'s holdings in Gilead Sciences were worth $17,758,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Personal CFO Solutions LLC raised its holdings in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company's stock worth $561,000 after acquiring an additional 76 shares during the last quarter. SOA Wealth Advisors LLC. boosted its stake in Gilead Sciences by 8.7% during the 4th quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company's stock valued at $125,000 after purchasing an additional 81 shares during the last quarter. Trivium Point Advisory LLC increased its holdings in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company's stock worth $813,000 after purchasing an additional 83 shares in the last quarter. Binnacle Investments Inc increased its holdings in shares of Gilead Sciences by 11.8% in the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company's stock worth $87,000 after purchasing an additional 83 shares in the last quarter. Finally, Hemington Wealth Management raised its stake in shares of Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company's stock worth $110,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider directly owned 128,779 shares in the company, valued at approximately $18,152,687.84. This represents a 2.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the sale, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 299,280 shares of company stock worth $42,920,450. Company insiders own 0.30% of the company's stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wells Fargo reiterated a buy rating on Gilead, supporting investor confidence in the company’s longer-term fundamentals. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
• Positive Sentiment: The U.S. Department of State expanded a partnership with Gilead and The Global Fund to provide 1 million doses of lenacapavir, boosting addressable market and public-health visibility for Gilead’s HIV prevention franchise. US-Led Partnership To Provide 1 Mln Lenacapavir To Help End HIV Transmission
• Positive Sentiment: Citigroup coverage remains constructive, with at least one analyst publicly saying GILD’s stock is expected to rise — a counterbalance to short‑term caution. Gilead Sciences NASDAQ: GILD Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Two insiders (including the CFO) sold small percentages of their positions via pre‑arranged Rule 10b5‑1 plans; such trades signal liquidity-taking rather than new negative information. SEC Form 4 (Andrew D. Dickinson)
• Neutral Sentiment: Gilead is expected to report quarterly results soon, which typically increases volatility as investors position around guidance and product trends. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: Media and analyst coverage (valuation pieces and trending‑stock notes) are driving attention but not yet altering fundamentals. Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns
• Negative Sentiment: RBC reported that persistence for Gilead’s HIV drug nine months after launch is weaker than expected — a potential hit to longer‑term revenue/kicker assumptions for the new product. Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
• Negative Sentiment: Zacks Research trimmed Q1–Q4 FY2026 EPS forecasts, lowering near‑term earnings expectations and increasing downside risk to consensus estimates. Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Broader health‑care stocks were softer late in the session, which amplified downward pressure on Gilead despite some stock‑specific positives. Sector Update: Health Care Stocks Decline Late Afternoon

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on GILD shares. Scotiabank raised their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 11th. Citigroup raised their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a "buy" rating in a report on Monday. Mizuho lifted their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a "neutral" rating in a research note on Thursday, January 8th. Finally, Daiwa Securities Group raised their price target on Gilead Sciences from $129.00 to $161.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $156.77.

Gilead Sciences Stock Down 0.9%

GILD opened at $138.55 on Friday. The stock has a market cap of $171.97 billion, a price-to-earnings ratio of 20.47, a price-to-earnings-growth ratio of 1.86 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The firm's fifty day moving average is $144.65 and its 200 day moving average is $131.10. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the company posted $1.90 EPS. The firm's revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio is presently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.